[Candida chorioretinitis: current therapeutic approach].
BACKGROUND
Candida endophthalmitis may occur either during systemic Candida infection (candidemia), particularly in immunocompromised hosts or as a single manifestation in drug abusers.


METHODS
One case of endogenous candida endophthalmitis (ECE) in a patient with systemic candidiasis and four cases of drug abusers are presented. Well confined inflammatory lesions in retina and choroid were adequately treated with systemic Amphotericin B administration, whereas lesion extension beyond the internal limiting membrane towards the vitreous required surgical management, to remove epiretinal fibrovascular tissue, and intravitreal Amphotericin B injection.


CONCLUSIONS
In all cases, treatment resulted to regression of the lesions, however visual function recovery depends on location of chorioretinal lesions.
Pournaras
C J
CJ
Clinique d'Ophtalmologie H.C.U. Genève.
Issoua
D
D
Saravelos
S
S
Sunaric
G
G
D000328:Adult; D000666:Amphotericin B / Q000008:administration & dosage*; D002177:Candidiasis / Q000188:drug therapy*; D002825:Chorioretinitis / Q000188:drug therapy; D003131:Combined Modality Therapy; D004305:Dose-Response Relationship, Drug; D009877:Endophthalmitis / Q000188:drug therapy*; D005260:Female; D006801:Humans; D007275:Injections, Intravenous; D008297:Male; D008875:Middle Aged; D009894:Opportunistic Infections / Q000188:drug therapy*; D014821:Vitrectomy
D000666:Amphotericin B
Choriorétinite à candida: approche thérapeutique actuelle.